How to buy Nurix Therapeutics stock

Nurix Therapeutics, Inc is a biotechnology business based in the US. Nurix Therapeutics shares (NRIX) are listed on the NASDAQ and all prices are listed in US Dollars. Nurix Therapeutics employs 135 staff and has a trailing 12-month revenue of around 0.00.

Nurix Therapeutics share price

Use our graph to track the performance of NRIX stocks over time.

Nurix Therapeutics shares at a glance

• Key figures

Information last updated 2021-04-21.

52-week range	$15.21 - $51.46
50-day moving average	$33.78
200-day moving average	$35.06
Wall St. target price	$48.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.82

Buy Nurix Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Nurix Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Nurix Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Nurix Therapeutics financials

Revenue TTM	$20 million
Gross profit TTM	$-48,674,000
Return on assets TTM	-19.82%
Return on equity TTM	-44.36%
Profit margin	-276.09%
Book value	N/A
Market capitalisation	$1.3 billion

TTM: trailing 12 months

Shorting Nurix Therapeutics shares

There are currently 4.3 million Nurix Therapeutics shares held short by investors – that's known as Nurix Therapeutics's "short interest". This figure is 60.3% up from 2.7 million last month.

There are a few different ways that this level of interest in shorting Nurix Therapeutics shares can be evaluated.

Nurix Therapeutics's "short interest ratio" (SIR)

Nurix Therapeutics's "short interest ratio" (SIR) is the quantity of Nurix Therapeutics shares currently shorted divided by the average quantity of Nurix Therapeutics shares traded daily (recently around 739676.41025641). Nurix Therapeutics's SIR currently stands at 5.85. In other words for every 100,000 Nurix Therapeutics shares traded daily on the market, roughly 5850 shares are currently held short.

However Nurix Therapeutics's short interest can also be evaluated against the total number of Nurix Therapeutics shares, or, against the total number of tradable Nurix Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Nurix Therapeutics's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Nurix Therapeutics shares in existence, roughly 100 shares are currently held short) or 0.1395% of the tradable shares (for every 100,000 tradable Nurix Therapeutics shares, roughly 140 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Nurix Therapeutics.

Find out more about how you can short Nurix Therapeutics stock.

Nurix Therapeutics share dividends

We're not expecting Nurix Therapeutics to pay a dividend over the next 12 months.

Nurix Therapeutics overview

Nurix Therapeutics, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; DeTIL-0255 for tumor infiltrating lymphocytes therapy; KINASE-CTM3 to treat T cell malignancies and autoimmune diseases; and LIGASE-INH2 for immuno-oncology. In addition, the company develops programs, such as COVID-CTM1, COVID-CTM2, and COVID-CTM3 that are designed for protein degradation to SARs CoV2 targets. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc.

Frequently asked questions

• What percentage of Nurix Therapeutics is owned by insiders or institutions?

  Currently 2.545% of Nurix Therapeutics shares are held by insiders and 73.251% by institutions.

• How many people work for Nurix Therapeutics?

  Latest data suggests 135 work at Nurix Therapeutics.

• When does the fiscal year end for Nurix Therapeutics?

  Nurix Therapeutics's fiscal year ends in November.

• Where is Nurix Therapeutics based?

  Nurix Therapeutics's address is: 1700 Owens Street, San Francisco, CA, United States, 94158

• What is Nurix Therapeutics's ISIN number?

  Nurix Therapeutics's international securities identification number is: US67080M1036